Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot reduce bladder leaks after childbirth?
The O-Shot may be discussed for selected post-childbirth bladder leakage, but only after assessment of leakage type, pelvic-floor function, healing history, prolapse symptoms, scar discomfort, breastfeeding/hormonal context, and severity.
Direct answer
The O-Shot may be discussed for selected post-childbirth bladder leakage, but only after assessment of leakage type, pelvic-floor function, healing history, prolapse symptoms, scar discomfort, breastfeeding/hormonal context, and severity.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
The Root Cause
Postpartum stress urinary incontinence (SUI) is very common and is caused by the extreme stretching and weakening.
The Treatment
The O-Shot is a non-surgical, minimally invasive therapy that utilizes autologous platelet-rich plasma (PRP) separated from a standard.
The Mechanism
PRP contains high concentrations of bioactive proteins and growth factors that trigger angiogenesis (new blood vessel formation), collagen.
The Outcome
The therapy enhances urethral closure pressure and structural tension, resulting in a reported decrease in leakage episodes.
Important safety note
Safety Profile: Because the O-Shot uses your own biological material (autologous blood), the risk of an allergic reaction, foreign body response, or immunogenic rejection is reduced, although not removed.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
• Investigational Status: While the centrifuge devices used to prepare the PRP are FDA-approved, the O-Shot procedure itself is currently considered an 'off-label' and investigational treatment for female stress urinary incontinence.
Clinical context
Investigational Status: While the centrifuge devices used to prepare the PRP are FDA-approved, the O-Shot procedure itself is currently considered an 'off-label' and investigational treatment for female stress.
Evidence
Symptoms
Alternatives
What it means
Investigational Status: While the centrifuge devices used to prepare the PRP are FDA-approved, the O-Shot procedure itself is currently considered an 'off-label' and investigational treatment for female stress.
Why it happens
Success Rates: Pilot clinical trials and cohort studies report improvement, with a 50% to 70% reduction in pad usage and reported improvements in validated incontinence scoring questionnaires.
Evidence limits
Comprehensive Care: The O-Shot is often more likely to be useful when integrated into a broader pelvic floor recovery plan.
Treatment fit
Suitability depends on history, symptoms, examination where appropriate and discussion of alternatives.
What this means in practice
• Preparation: Patients are advised to stay well-hydrated before the blood draw, abstain from alcohol and smoking, and avoid blood-thinning medications like NSAIDs (aspirin, ibuprofen) for at least 1 to 2 weeks prior to the procedure.
• Procedure Time: The entire treatment is completed in-office and typically takes 30 to 60 minutes from the blood draw to the final injection.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
Investigational Status: While the centrifuge devices used to prepare the PRP are FDA-approved, the O-Shot procedure itself is currently considered an 'off-label' and investigational treatment for female stress.
It protects safety
Safety Profile: Because the O-Shot uses your own biological material (autologous blood), the risk of an allergic reaction, foreign body response, or immunogenic rejection is reduced, although not removed.
It reviews alternatives
Preparation: Patients are advised to stay well-hydrated before the blood draw, abstain from alcohol and smoking, and avoid blood-thinning medications like NSAIDs (aspirin, ibuprofen) for at least 1.
It sets expectations
Procedure Time: The entire treatment is completed in-office and typically takes 30 to 60 minutes from the blood draw to the final injection.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
• Preparation: Patients are advised to stay well-hydrated before the blood draw, abstain from alcohol and smoking, and avoid blood-thinning medications like NSAIDs (aspirin, ibuprofen) for at least 1 to 2 weeks prior to the procedure.
Consultation priorities
Consultation: The journey starts with a comprehensive medical evaluation to assess your postpartum incontinence symptoms, childbirth trauma, and overall pelvic health to confirm you are an ideal candidate.
Consent
Aftercare
Follow-up
Before treatment
Consultation: The journey starts with a comprehensive medical evaluation to assess your postpartum incontinence symptoms, childbirth trauma, and overall pelvic health to confirm you are an ideal candidate.
During care
Preparation & Blood Draw: A small sample of blood is drawn from your arm and spun in a specialised centrifuge for about 20-30 minutes to separate and isolate.
Aftercare
Treatment: After numbing the target areas, the provider carefully injects the PRP into specific locations, such as the periurethral spaces and the anterior vaginal wall.
When to reassess
Aftercare: You will be discharged the same day with straightforward aftercare instructions. Improvements in bladder control will begin to emerge gradually over the following weeks.
Practical expectations
Procedure Time: The entire treatment is completed in-office and typically takes 30 to 60 minutes from the blood draw to the final injection.
Pain Management: The treatment area is generously pre-treated with a strong topical numbing cream (such as BLT cream) and local anaesthesia, ensuring the injections are comfortable and relatively.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Leaking after childbirth is something women must live with.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: PRP is the first step for every postpartum bladder symptom.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: Childbirth leakage always has one simple cause.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Success Rates: Pilot clinical trials and cohort studies report improvement, with a 50% to 70% reduction in pad usage and reported improvements in validated incontinence scoring questionnaires.
Alternatives
Preparation: Patients are advised to stay well-hydrated before the blood draw, abstain from alcohol and smoking, and avoid blood-thinning medications like NSAIDs (aspirin, ibuprofen) for at least 1.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Safety Profile: Because the O-Shot uses your own biological material (autologous blood), the risk of an allergic reaction, foreign body response, or immunogenic rejection is reduced, although not removed.
Are alternatives clear?
Preparation: Patients are advised to stay well-hydrated before the blood draw, abstain from alcohol and smoking, and avoid blood-thinning medications like NSAIDs (aspirin, ibuprofen) for at least 1.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Safety Profile: Because the O-Shot uses your own biological material (autologous blood), the risk of an allergic reaction, foreign body response, or immunogenic rejection is reduced, although not removed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Safety Profile: Because the O-Shot uses your own biological material (autologous blood), the risk of an allergic reaction, foreign body response, or immunogenic rejection is reduced, although not removed.
Bleeding or discharge
Common Side Effects: Patients may experience mild and temporary side effects such as slight soreness, minor swelling, redness, or light spotting at the injection sites, which usually resolve.
Infection signs
Contraindications: PRP therapy is not suitable for women with active pelvic or urinary tract infections, severe anemia, blood clotting disorders, those who are currently pregnant, or individuals taking.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The strongest page combines empathy with proper triage: childbirth history matters, pelvic-floor assessment matters, and PRP is only one possible discussion.
Clinical reality
- Investigational Status: While the centrifuge devices used to prepare the PRP are FDA-approved, the O-Shot procedure itself is currently considered an 'off-label' and investigational treatment for female stress urinary incontinence.
- Success Rates: Pilot clinical trials and cohort studies report improvement, with a 50% to 70% reduction in pad usage and reported improvements in validated incontinence scoring questionnaires (like ICIQ-SF and UDI-6).
- Comprehensive Care: The O-Shot is often more likely to be useful when integrated into a broader pelvic floor recovery plan.
Timeline and expectations
- Procedure Time: The entire treatment is completed in-office and typically takes 30 to 60 minutes from the blood draw to the final injection.
- Initial Results: While some women notice improvements in sensitivity and reduced leakage within 3 to 7 days, it generally takes a few weeks to begin seeing notable changes.
- Peak Benefits: The best reported response is often assessed around 3 to 4 months post-treatment as new, healthy tissue fully develops.
- Longevity: The positive effects are long-lasting but not expected to be indefinite.
Practical logistics
- Preparation: Patients are advised to stay well-hydrated before the blood draw, abstain from alcohol and smoking, and avoid blood-thinning medications like NSAIDs (aspirin, ibuprofen) for at least 1 to 2 weeks.
- Pain Management: The treatment area is generously pre-treated with a strong topical numbing cream (such as BLT cream) and local anaesthesia, ensuring the injections are managed with local anaesthesia.
- Downtime: Usually little recovery time is needed; most patients can immediately return to work and routine daily activities following the appointment.
- Restrictions: To allow the tissues to heal, patients are usually instructed to abstain from sexual intercourse, tampon use, and strenuous physical exercise for 24 to 72 hours post-procedure.
- Costs should be confirmed on the /pricing/ page before booking
Research sources
- Borislavschi, A., et al. (2026). 'Comparing Regenerative and Rehabilitative Strategies for Female Stress Urinary Incontinence: Platelet-Rich Plasma vs. Pelvic Floor Muscle Training—A Prospective Study Evaluating Quality of Life.' Bioengineering.
- Dankova, I., et al. (2023). 'Efficacy and Safety of Platelet-Rich Plasma Injections for the Treatment of Female Sexual Dysfunction and Stress Urinary Incontinence: A Systematic Review.' Biomedicines.
- Long, C.Y., et al. (2021). 'A pilot study: Effectiveness of local injection of autologous platelet-rich plasma in treating women with stress urinary incontinence.' Scientific Reports.
- Jiang, Y.H., et al. (2021). 'Therapeutic Efficacy of Urethral Sphincter Injections of Platelet-Rich Plasma for the Treatment of Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency: A Proof-of-Concept Clinical Trial.' International Neurourology Journal.
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 152 imported records. Additional reviewed material included UK clinical guidance, professional society guidance, peer-reviewed clinical papers, evidence reviews; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. The information provided in this clinical briefing is for educational and informational purposes only and is not intended to serve as professional medical advice, diagnosis, or treatment. Always consult with your physician, urogynaecologist, or a qualified healthcare provider regarding your specific pelvic floor condition or before undergoing investigational procedures such as the O-Shot. Results vary. Not a cure.
